(Q36139273)

12 August 2017

1 reference

title

Infliximab: in ankylosing spondylitis (English)

1 reference

12 August 2017

2

Gillian M Keating

1 reference

12 August 2017

Dean M Robinson

1

1 reference

12 August 2017

publication date

1 January 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

65

1 reference

12 August 2017

issue

9

1 reference

12 August 2017

page(s)

1283-91; discussion 1292-4

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200565090-00006

12 August 2017

exact match

0 references

cites work

A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index

1 reference

12 December 2020

Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study

1 reference

12 December 2020

Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis

1 reference

12 December 2020

Biological therapies in the spondyloarthritides--the current state

1 reference

12 December 2020

Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis

1 reference

12 December 2020

Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study

1 reference

12 December 2020

Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy.

1 reference

12 December 2020

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

12 December 2020

Immunological basis for the use of TNFalpha-blocking agents in ankylosing spondylitis and immunological changes during treatment

1 reference

12 December 2020

Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.

1 reference

12 December 2020

Safety of tumour necrosis factor-alpha antagonists

1 reference

12 December 2020

Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)

1 reference

12 December 2020

Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab

1 reference

12 December 2020

Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis

1 reference

12 December 2020

Anti-TNF agents for the treatment of spondyloarthropathies

1 reference

12 December 2020

Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab

1 reference

12 December 2020

Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis

1 reference

12 December 2020

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

1 reference

12 December 2020

International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis

1 reference

12 December 2020

Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis

1 reference

12 December 2020

Effect of infliximab treatment on T cell cytokine responses in spondylarthropathy: comment on the article by Zou et al.

1 reference

12 December 2020

Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis

1 reference

12 December 2020

Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study

1 reference

12 December 2020

Treatment of spondyloarthropathies with antibodies against tumour necrosis factor alpha: first clinical and laboratory experiences

1 reference

12 December 2020

Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity

1 reference

12 December 2020

Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial

1 reference

12 December 2020

The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade).

1 reference

12 December 2020

Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system

1 reference

12 December 2020

Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index.

1 reference

12 December 2020

A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index

1 reference

12 December 2020

10.2165/00003495-200565090-00006

Identifiers

DOI

1 reference

Dimensions Publication ID

12 August 2017

1013748608

0 references

Fatcat ID

release_ttkgbwukbvcmbmvw7rlasbhqai

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ttkgbwukbvcmbmvw7rlasbhqai

24 November 2022

mapped directly with Wikidata item

1 reference